ClinicalTrials.gg

Program

Travoprost

Also written as “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, “Travoprost 0.004% / Timolol maleate 0.5%” and “Travoprost 0.004% ophthalmic solution”.

Its studies are mostly in Glaucoma, Open-Angle · Glaucoma · Glaucoma, Angle-Closure · Low Tension Glaucoma · Hydrophthalmos, led by 5 companies.

Furthest: phase 4, since May 28, 200363 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon520 open or runningphase 4since May 28, 2003Jan 3, 2003none ahead
Glaukos72 open or runningphase 4since Sep 28, 2011Sep 28, 2011none ahead
Ocular Therapeutix20 open or runningphase 3since Sep 21, 2016Dec 4, 2014none ahead
Laboratorios Sophia S.A de C.V.10 open or runningphase 1since May 23, 2019May 23, 2019none ahead
Viatris10 open or runningphase 4since Feb 16, 2009Feb 16, 2009none ahead

Also a collaborator on its studies: ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since May 28, 2003.

  1. Jul 26, 2012Phase 3 study in HydrophthalmosAlcon · NCT01652664 · 184 enrolled
  2. Aug 3, 2012Phase 1 study in GlaucomaAlcon · NCT01658839 · 25 enrolled
  3. Aug 10, 2012Phase 4 study in GlaucomaAlcon · NCT01664039 · 104 enrolled
  4. Sep 27, 2012Phase 4 study in GlaucomaAlcon · NCT01696383
  5. Nov 21, 2013Phase 4 study in Low Tension GlaucomaAlcon · NCT01995136 · 32 enrolled · Japan
  6. Dec 2, 2013Phase 4 study in Glaucoma, Open-AngleAlcon · NCT02003391 · 157 enrolled
  7. Dec 4, 2014Ocular Therapeutix's first study: phase 2 study in GlaucomaNew to Ocular TherapeutixOcular Therapeutix · NCT02312544 · 72 enrolled · United States
  8. Aug 11, 2016Phase 4 study in Glaucoma, Open-AngleGlaukos · NCT02873806 · 53 enrolled · Armenia
  9. Sep 21, 2016Phase 3 study in Glaucoma, Open-AngleOcular Therapeutix · NCT02914509 · 565 enrolled · United States
  10. May 23, 2019Laboratorios Sophia S.A de C.V.'s first study: phase 1 study in GlaucomaNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT03965052 · 24 enrolled · Mexico
  11. Oct 29, 2020Phase 2 study in Glaucoma, Open-AngleGlaukos · NCT04615403 · 33 enrolled · United States, Philippines
  12. Sep 25, 2023Phase 3 study in Glaucoma, Open-AngleGlaukos · NCT06061718 · 60 enrolled · Armenia
  13. Aug 30, 2024Phase 2 study in Glaucoma, Open-AngleGlaukos · NCT06582732 · 210 enrolled · Armenia
  14. Feb 1, 2025Phase 4 study in Glaucoma, Open-AngleGlaukos · NCT06848946 · 132 planned · United States

TargetBeta

PTGFR →read by rule
“Prostanoid FP receptor agonist”ChEMBL 37, by rule

Other programs on PTGFR

ProgramCompanyFurthest phaseStudies
AGN-193408AbbViephase 21

Studies

The newest 60 of 63 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT06848946Glaucoma, Open-Angle · United States4RecruitingGlaukosAug 2026132
NCT06582732Glaucoma, Open-Angle · Armenia2CompletedGlaukosNov 2, 2023210
NCT06061718Glaucoma, Open-Angle · Armenia3Active, not recruitingGlaukosMar 18, 202460
NCT04615403Glaucoma, Open-Angle · United States, Philippines2CompletedGlaukosFeb 28, 202233
NCT03965052Glaucoma · Mexico1CompletedLaboratorios Sophia S.A de C.V.Jul 2, 201924
NCT02914509Glaucoma, Open-Angle · United States3CompletedOcular TherapeutixMar 30, 2019565
NCT02873806Glaucoma, Open-Angle · Armenia4CompletedGlaukosNov 8, 201953
NCT02312544Glaucoma · United States2CompletedOcular TherapeutixSep 201572
NCT02003391Glaucoma, Open-Angle4CompletedAlconMay 2015157
NCT01995136Low Tension Glaucoma · Japan4CompletedAlconJun 201432
NCT01696383Glaucoma4WithdrawnAlconFeb 20130
NCT01664039Glaucoma4CompletedAlconJun 2014104
NCT01658839Glaucoma1CompletedAlconJul 201325
NCT01652664Hydrophthalmos3CompletedAlconMar 2014184
NCT01510145Glaucoma, Open-Angle4CompletedAlconMay 2013191
NCT01510132Glaucoma, Open-Angle4WithdrawnAlconJan 20120
NCT01493427Glaucoma, Open-Angle4CompletedAlconFeb 2013202
NCT01464424Glaucoma4CompletedAlconJun 201284
NCT01453855Glaucoma, Open-Angle3CompletedAlconAug 20121,099
NCT01452009Glaucoma, Open-Angle3WithdrawnAlconDec 20110
NCT01444040Glaucoma, Open-Angle · Armenia4CompletedGlaukosMar 28, 2019196
NCT01443988Glaucoma, Open-Angle · Armenia4CompletedGlaukosJan 2017101
NCT01336569Glaucoma · United States4CompletedAlconMar 201250
NCT01327599Glaucoma, Open-Angle4CompletedAlconNov 201260
NCT01298687Glaucoma, Open-Angle2CompletedAlconApr 201167
NCT01230736Glaucoma · Germany4CompletedAlconFeb 2011105
NCT01114893Glaucoma, Open-Angle · United States2CompletedAlconMay 201060
NCT00966940Glaucoma4CompletedAlconMar 201051
NCT00928590Glaucoma, Open-Angle3CompletedAlconNov 2010155
NCT00872651Glaucoma, Open-Angle · China3CompletedAlconNov 2011242
NCT00848536Glaucoma, Open-Angle3CompletedAlconJan 2010371
NCT00847483Glaucoma · United States4CompletedViatrisAug 2002375
NCT00798759Glaucoma, Open-Angle4CompletedAlconMay 2009236
NCT00767494Glaucoma · Belgium3TerminatedAlconFeb 200917
NCT00767481Glaucoma · Mexico3TerminatedAlconFeb 20096
NCT00763061Glaucoma · United States4CompletedAlconApr 2008111
NCT00761319Glaucoma, Open-Angle3CompletedAlconSep 2009705
NCT00762645Glaucoma, Angle-Closure4CompletedAlconMay 200830
NCT00760539Glaucoma, Open-Angle · Japan3CompletedAlconDec 200887
NCT00759239Glaucoma, Open-Angle · United Kingdom4CompletedAlconJan 201136
NCT00758342Intraocular Pressure4TerminatedAlconMar 200837
NCT00708422Glaucoma4CompletedAlconAug 2009231
NCT00690794Glaucoma, Open-Angle3CompletedAlconMay 2009726
NCT00672997Glaucoma, Open-Angle3CompletedAlconDec 2008301
NCT00670033Ocular Hypertension2CompletedAlconSep 2008158
NCT00527592Glaucoma, Open-Angle4CompletedAlconAug 200854
NCT00527501Glaucoma, Open-Angle · United States2CompletedAlconDec 2007136
NCT00519753Glaucoma · Germany4CompletedAlconDec 2008522
NCT00508469Glaucoma, Open-Angle · Spain4CompletedAlconJan 2010102
NCT00471380Glaucoma · Italy4CompletedAlconOct 200846
NCT00471068Glaucoma, Open-Angle · Portugal4TerminatedAlconAug 200846
NCT00468988Glaucoma · United States4CompletedAlconJul 200730
NCT00465803Glaucoma, Open-Angle · United States3CompletedAlconJan 200981
NCT00444665Glaucoma · United States4CompletedAlconAug 2007750
NCT00333125Glaucoma3CompletedAlconFeb 2007319
NCT00311389Glaucoma, Open-Angle · Belgium3CompletedAlconSep 2004408
NCT00293800Glaucoma, Open-Angle3CompletedAlconDec 2005173
NCT00293787Glaucoma, Open-Angle3CompletedAlconAug 2005156
NCT00288951Glaucoma, Open-Angle3CompletedAlconJun 2005690
NCT00061503Glaucoma · United States4CompletedAlconMar 2004

How it is read

Names in the registry

  • “Travoprost”, 6 entries
  • “Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)”, 5 entries
  • “Travoprost 0.004% / Timolol maleate 0.5%”, 2 entries
  • “Travoprost 0.004% ophthalmic solution”, 2 entries
  • “Travoprost ophthalmic solution, 0.004%”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.